Comparative study of the formation and repair of O6-methylguanine in humans and rodents treated with dacarbazine

Carcinogenesis

Volumn 17, Issue 4, 1996, Pages 725-732

  Souliotis, Vassilis L ^a   Valavanis, Christos ^a   Boussiotis, Viki A ^b   Pangalis, Gerasimos A ^b   Kyrtopoulos, Soterios A ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O METHYLGUANINE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA REPAIR; DRUG DNA INTERACTION; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; LEUKOCYTE; LIVER; LYMPH NODE; MALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RAT; VARIANCE;

ANIMALS; DACARBAZINE; DNA DAMAGE; DNA REPAIR; FEMALE; GUANINE; HODGKIN DISEASE; HUMANS; MALE; METHYLTRANSFERASES; MICE; MICE, INBRED BALB C; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 0029923258     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.4.725     Document Type: Article

References (43)

1. Legha,S.S, (1989) Current therapy for malignant melanoma. Semin. Oncol., 16, 34-44.
2. McClay,E.F. and Mastrangelo,M.J. (1988) Systemic chemotherapy for metastatic melanoma Semin. Oncol., 15, 569-577
3. Bonadonna,G. and Santoro,A. (1982) Evolution in the treatment strategy of Hodgkin's disease Adv. Cancer Res., 36, 257-293.
4. Valagussa,P., Santoro, A., Fossati-Bellani,F, Franchi,F., Banfi,A., Rilke,F. and Bonadonna,G (1982) Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood, 59, 488-494.
5. van Leeuwen,F.E., Chorus,A.M.J., van den Belt,A.W., Hagenbeek,A., Noyon,R., van Kerkhoff,E.H M., Pinedo,H.M. and Somers,R. (1994) Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage J. Clin. Oncol, 12. 1063-1073.
6. - phenotypes by a series of alkyltriazenylimidazoles. Carcinogenesis, 7, 259-265.
7. Bartoli-Klugmann,F., Pani,B., Babudn,N., Montibragadin,C., Tamaro,M. and Venturini,S. (1982) In vitro mutagenic activity of 5-(3.3-dimethyl-1-triazeno)imidazole-4-carboxamide (Dacarbazine) in eukaryotic and prokaryotic cells. Carcinogenesis, 3, 467-471.
8. - cell lines: differential potentiation by 3-acetamidobenzamide Br. J. Cancer. 57, 54-58.
9. Beal,D.D., Skibba,J.L., Croft,W.A., Cohen,S.M. and Bryan,G.T. (1975) Carcinogenicity of the antineoplastic agent 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats. J. Ntel Cancer Inst., 54, 951-957.
10. Weisburger,J.H., Griswold,D.P, Prejean,J.D., Casey,A.E., Wood,H.B. and Weisburger,E.K, (1975) The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. Recent Results Cancer Res., 52, 1-17
11. Weisburger,E.K. (1977) Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer, 40, 1935-1951.
12. Skibba,J.L., Beal,D.D., Ramirez,G. and Bryan,G.T. (1970) N-Demethylation of the antineoplastic agent 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide by rats and man. Cancer Res., 30, 147-150.
13. Mizuno,N.S. and Decker,R.W. (1976) Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347). Biochem. Pharmacol., 25, 2643-2647.
14. Meer,L., Janzer,R C., Kleihues,P. and Kolar,G.F. (1986) in vivo metabolism and reaction with DNA of the cytostatic agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (dacarbazine). Biochem. Pharmacol., 35, 3243-3247.
15. 6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine. Carcinogenesis, 12, 285-288.
16. 6-methyldeoxyguanosme in human leukocyte DNA following sequential Dacarbazine and fotemustine chemotherapy. Br. J. Cancer, 69, 853-857.
17. Philip,P.A., Souliotis,V.L., Harris,A.L., Salisbury,A., Tates,A.D., Mitchell,K., van Delft,J.H.M., Ganesan,T.S. and Kyrtopoulos,S.A. (1996) Methyl DNA adducts. DNA repair and HPRT mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea Clin. Cancer Res., in press.
18. 6-methylguanine synthesized at the rat H-ras N-methyl-N-nitrosourea activation site and introduced into Escherichia coli. Carcinogenesis, 10, 373-377.
19. 6-methyaguanine in DNA - the crucial role of the conformation of the phosphodiester bond. Biochemistry, 33, 5335-5346.
20. 6-methylguanine in the human Ha-ras oncogene in E.coli and in vitro Nucleic Acids Res., 22, 3846-3853.
21. Mirsalis,J.C., Monforte,J.A. and Winegan,R.A. (1994) Transgenic animal models for measuring mutations in vivo. Crit. Rev. Toxicot., 24, 255-280.
22. 6-alkylguanine DNA repair activity during continuous exposure to carcinogen. Proc. Nail Acad. Sci. USA. 79, 5499-5502.
23. 6-methylguanine preferentially accumulates in target cell DNA during continuous exposure of rats to 1.2-dimethylhydrazine. Cancer Res., 42, 3079-3083.
24. 6-alkylguanine-DNA alkyltransferase. Science, 259, 219-222.
25. 6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc. Natl Acad. Sci. USA, 90, 6468-6472.
26. Zaidi,N H., Pretlow,T.P., Oriordan,M.A., Dumenco,L.L., Allay,E. and Gerson,S.L. (1995) Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis, 16, 451-456
27. 6-alkylauanine-DNA alkyltransferase reduces the toxic effects of alkylating agents. Carcinogenesis, 7, 2081-2084.
28. - phenotypes by a series of 1-aryl-3-alkyltriazenes. Cancer Res., 46, 4999-5003.
29. 6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis, 12, 1857-1867
30. 6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treatment Rev., 15, 279-292.
31. Zhukovskaya,N., Branch.P., Aquilina,G. and Karran,P. (1994) DNA replication arrest and tolerance to DNA metnylation damage. Carcinogenesis. 15, 2189-2194.
32. 6-alkylguanine-DNA alkyltransferase in rat tissues. Carcinogenesis, 15, 1681-1688.
33. 6-methylguanine. Cancer Res., 49. 6997-7001
34. Freireich,E.J., Gehan,E.A., Rall,D.P., Schmidt,L.H. and Skipper,H.E. (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep., 50, 219-244.
35. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br. J. Cancer. 67, 216-221.
36. 6-Alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes followins dacarbazine and fotemustine. Cancer Res., 51, 619-623.
37. 6-methylguanine in humans and rodents treated with procarbazine. Carcinogenesis, 15, 1675-1680.
38. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res., 50, 2759-2764.
39. Kolar,G.F., Maurer,M. and Wildschutte,M. (1980) 5-(3-Hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DIC, DTIC NSC-45388). Cancer Lett., 10, 235-241.
40. 6-methyleuanine from DNA. Mutat. Res., 95, 405-416.
41. Lee,S.M., Margison,G.P., Woodcock,A.A., and Thatcher,N. (1993) Sequential administration of varying doses of dacarbazine and fotemnstine in advanced malignant melanoma. Br. J. Cancer. 67, 1356-1360.
42. Reed,E., Ozols,R.F., Tarone,R., Yuspa,S.H. and Poirier,M.C. (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl Acad Sci. USA. 84, 5024-5028.
43. Reed,E., Ostchenga,Y., Steinberg,S.M., Yuspa,S.H., Young,R.C., Ozols,R.F. and Poirier,M.C. (1990) Evaluation of platinum-DNA adduct levels relative to the known prognostic variables in a cohort of ovarian cancer patients Cancer Res., 50, 2256-2260.